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Abstract: Transplantation of mesenchymal stem cells (MSCs) has paracrine effects; however,
the effects are known to be largely limited. Here we investigated the combination effects of
cell transplantation and enriched environment (EE) in a model of hypoxic-ischemic brain injury.
Brain damage was induced in seven-day-old mice by unilateral carotid artery ligation and exposure
to hypoxia (8% O2 for 90 min). At six weeks of age, the mice were randomly assigned to four groups:
phosphate-buffered saline (PBS)-control (CON), PBS-EE, MSC-CON, and MSC-EE. Rotarod and
grip strength tests were performed to evaluate neurobehavioral functions. Histologic evaluations
were also performed to confirm the extent of astrocyte activation and endogenous angiogenesis.
An array-based multiplex ELISA and Western blot were used to identify growth factors in vivo and
in vitro. Two weeks after treatment, levels of astrocyte density and angiogenic factors were increased
in MSC-EE mice, but glial scarring was not increased. Eight weeks after treatment, angiogenesis
was increased, and behavioral outcomes were synergistically improved in the MSC-EE group.
Astrocytes co-cultured with MSCs expressed higher levels of angiogenic factors than astrocytes
cultured alone. The mechanisms of this synergistic effect included enhanced repair processes,
such as increased endogenous angiogenesis and upregulation of angiogenic factors released from
activated astrocytes.
Keywords: hypoxic-ischemic brain injury; mesenchymal stem cells; enriched environment;
angiogenesis; astrocytes
1. Introduction
An enriched environment (EE) has been a classic paradigm for studying the effects of a complex
combination of physical, cognitive, and social stimulation in rodents [1,2]. An EE including running
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wheels, novel objects, and social interactions is a model of rehabilitation in rodents. In many studies,
an EE has exhibited therapeutic effects such as enhancement of neurogenesis [3], angiogenesis [4],
neural plasticity [5], and astroglial activation without glial scarring [3] via secretion of beneficial factors
in a normal or injured brain. These effects have been hypothesized to lead to functional recovery [3,4].
Multipotent mesenchymal stem cells (MSCs) derived from adipose are abundantly harvested from
lipoaspirates and are not associated with ethical or immunological problems [6–8]. Although MSCs
can differentiate into cells of the neural lineage in vitro and express neuronal or glial markers in the
ischemic brain of animal models [9–13], we previously demonstrated the low survival rate of MSCs
and number of differentiated cells into βIII-tubulin+ neuronal cells after MSC transplantation into
the brain. Indeed, recent evidence suggests that transplanted MSCs also secrete various paracrine
factors, including cytokines, chemokines, and growth factors [6,14]. Moreover, MSCs treated group
showed transient improvements in neuronal behavioral assessments [3]. These findings suggest that
the beneficial effects of MSCs are due to indirect paracrine mechanisms rather than cell replacement
and direct tissue regeneration [3,15,16]; thus, transplantation of adipose-derived MSCs may result in
limited and transient effects instead of long-lasting permanent improvement [3].
Astrocytes are the most abundant cells in the brain and play a crucial role in the formation of the
blood brain barrier (BBB) via their endfeet processes. However, excessive reactivation of astrocytes
leads to the retraction of astrocyte endfeet from vessels and increased glial scarring [17–20]. Park et al.
showed that MSCs stabilize the BBB by regulating astrocytic endfeet and vascular endothelial growth
factor (VEGF-A) signaling [17]. Other studies have shown that astrocytes secrete glial cell-derived
neurotrophic factor (GDNF) [21,22], VEGF [22–24], fibroblast growth factor-2 (FGF-2) [22,25], and
brain-derived neurotrophic factor (BDNF) [22,26] after MSC transplantation. Therefore, reactive
astrocytes promote recovery from injury after MSCs grafting.
We have previously shown that an EE enhances the engraftment of transplanted MSCs by
providing a beneficial microenvironment, and that the combination of an EE and MSCs induces
astrocyte activation and FGF-2 secretion [3]. In the present study, we further investigated whether
astrocytes activated by an EE after MSC transplantation can induce angiogenesis and other processes
that cause functional recovery.
2. Results
2.1. The Combination of an Enriched Environment (EE) and Mesenchymal Stem Cells (MSCs) Induces
Astrocyte Activation
Astrocytes play crucial roles in the recovery of the injured brain. Thus, we evaluated the levels of
activated astrocytes after treatment with MSCs and/or an EE in a model of hypoxic-ischemic brain
injury (Figure 1). The density of striatal GFAP+ cells (%) was calculated as the GFAP+ area (in mm2)
divided by the striatal area (in mm2). The GFAP+ cell density was significantly increased in the
MSC-EE group at two weeks post-treatment (Figure 2A,C–J; p < 0.01 and p < 0.05 compared with
PBS-CON and PBS-EE, respectively). Specifically, the GFAP+ cell densities were MSC-EE (8.8% ± 1.8%),
MSC-CON (5.7% ± 1.1%), PBS-EE (3.5% ± 0.4%), and PBS-CON (3.0% ± 1.0%). At eight weeks
post-treatment, the MSC-EE group exhibited a significant increase (Figure 2A; p < 0.05 compared
with PBS-CON): MSC-EE (3.1% ± 0.7%), MSC-CON (1.4% ± 0.5%), PBS-EE (1.7% ± 0.6%), and
PBS-CON (1.0% ± 0.3%). In addition, the level of the glial scarring marker CS-56 did not differ among
the groups (Figure 2B,K–N), demonstrating that the combination of an EE and MSCs does not result in
glial scarring, which inhibits neuronal regeneration after injury. This result suggests that an EE was
able to sustain endogenous astrocyte activation after transplantation of MSCs in a synergistic manner.
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Figure 1. Experimental designs: (A) Schematic timeline of the experimental procedures; (B) mice 
were monitored in hypoxic conditions (8% O2) controlled with N2 gas for 90 min after unilateral 
carotid artery ligation; (C) in the left and middle panels, the damaged brain showed an ipsilateral 
lesion in the posterolateral hemisphere, while the right panel in the red box shows that severely 
injured mice were excluded from this study; and (D) an enriched environment, including tunnels, 
shelters, toys, running wheels for voluntary exercise, and social interaction and standard cage at the 
right bottom. 
 
Figure 2. The combination of MSCs and an EE induces astrocyte activation. (A–N) Two and eight 
weeks after an EE and MSC transplantation, the amounts of GFAP+ cells (green color) and CS-56+ 
cells (red color) were evaluated using the MetaMorph Imaging System. (A) The density of striatal 
GFAP+ cells (%) was significantly higher in the MSC-EE mice than in both the PBS-CON and PBS-EE 
groups two weeks after treatment (* p < 0.05 and ** p < 0.01, respectively; n = 5 each); (B) The CS-56+ 
cell density did not differ between groups; (C–N) Two weeks after an EE and MSC transplantation, 
representative images are shown. Scale bars = 100 μm. Values represent mean + SEM. 
Figure 1. Experimental designs: (A) Schematic timeline of the experimental procedures; (B) mice were
monitored in hypoxic conditions (8% O2) controlled with N2 gas for 90 min after unilateral carotid
artery ligation; (C) in the left and middle panels, the damaged brain showed an ipsilateral lesion in the
posterolateral hemisphere, while the right panel in the red box shows that severely injured mice were
excluded from this study; and (D) an enriched environment, including tunnels, shelters, toys, running
wheels for voluntary exercise, and social interaction and standard cage at the right bottom.
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Figure 2. The combination of MSCs and an EE induces astrocyte activation. (A–N) Two and eight weeks
after an EE and MSC transplantation, the amounts of GFAP+ cells (green color) and CS-56+ cells
(red color) were evaluated using the MetaMorph Imaging System. (A) The density of striatal GFAP+
cells (%) was significantly higher in the MSC-EE mice than in both the PBS-CON and PBS-EE groups
two weeks after treatment (* p < 0.05 and ** p < 0.01, respectively; n = 5 each); (B) The CS-56+ cell density
did not differ between groups; (C–N) Two weeks after an EE and MSC transplantation, representative
images are shown. Scale bars = 100 µm. Values represent mean + SEM.
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2.2. The Combination of an EE and MSCs Enhances Endogenous Angiogenesis
Based on our finding that the combination of an EE and MSCs resulted in increased astrocyte
activation, we quantified the extent of angiogenesis induction in the neostriatum. We focused on this
parameter because of the crucial role of astrocytes in maintaining the integrity of the BBB. The ability
of MSC transplantation in combination with an EE to induce endogenous angiogenesis was assessed
by histological analysis. Specifically, the densities of α-SMA-positive and CD31-positive cells were
determined (Figure 3A–J). At two weeks post-treatment, the MSC-EE mice exhibited a modest tendency
to exhibit enhanced angiogenesis, but no significant differences were observed among the other groups.
Interestingly, the densities of α-SMA-positive and CD31-positive cells at two weeks post-treatment
were higher than at eight weeks, but the differences were not statistically significant. The density
of α-SMA+ cells in the MSC-EE group (0.18% ± 0.04%) was significantly higher than in the MSC-CON
(0.04% ± 0.01%), PBS-EE (0.06% ± 0.02%), and PBS-CON groups (0.03% ± 0.01%) (Figure 3A,C–F;
p < 0.01 compared with MSC-CON, p < 0.05 compared with PBS-EE, and p < 0.001 compared
with PBS-CON). Likewise, the density of CD31+ cells was significantly increased in the MSC-EE
(0.28% ± 0.08%) group compared with the MSC-CON (0.09% ± 0.03%), PBS-EE (0.1% ± 0.02%), and
PBS-CON groups (0.03% ± 0.01%) (Figure 3B,G–J; p < 0.05 compared with MSC-CON and PBS-EE,
and p < 0.01 compared with PBS-CON, respectively). Therefore, at eight weeks post-treatment, mice
treated with an EE after MSC transplantation showed significant induction of angiogenesis in the
neostriatum. We co-stained brain sections with GFAP and CD31, and the result showed that CD31+
cells were surrounded with GFAP+ astrocytes. This finding suggests that astrocytes were associated
with endothelial cells (Figure 3K–M).
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significantly increased in the MSC-EE group compared with the PBS-CON groups at two weeks 
post-treatment (Figure 4A–C; p < 0.01 and p < 0.05). However, the following factors were not 
synergistically elevated in mice treated with the MSC-EE combination compared with mice in the 
other groups: epidermal growth factor (EGF), granulocyte colony-stimulating factor (GCSF), 
hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), leptin, stromal cell-derived 
factor-1 (SDF-1), and VEGF. These results suggest that angiogenic factors such as FGF-2, VCAM-1, 
and MMP-2 secretion were enhanced through an EE after MSC transplantation, and that this role 
may involve angiogenesis and activated astrocytes. To identify the growth factors derived from 
which origin, mouse or human cells, we assessed these factors using a human-specific array-based 
multiplex ELISA assay. As a result, 10 candidate factors were not synergistically elevated. 
Furthermore, the levels of growth factors derived from mouse cells were expressed markedly 
higher than those from human-derived MSCs (Figure 4A–J). This result suggested that these factors 
were derived from mouse cells not human origin. 
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Figure 3. The Combination of MSCs and an EE enhanced endogenous angiogenesis in the striatum.
(A–J) Two and eight weeks after an EE and MSC transplantation, the amounts of α-SMA+ cells (A) and
CD31+ cells (B) were quantified using the MetaMorph Imaging System. Red color indicates α-SMA+
cells (C–F) and CD31+ cells (G–J). The density of: (A) striatal α-SMA+ cells (%) was significantly
higher i the MSC-EE mice than in the PBS-CON, PBS-EE, and MSC CON eight weeks after treatment
(white arrows); and (B) CD31+ cells were signifi antly higher i stria um of the MSC-EE ice than
in those of the other gr ups a eight weeks ost-treatment (* p < 0.05, ** p < 0.01, and *** p < . 01,
respectively; n = 5 each); (C–J) Eight weeks after EE and MSC transplantation, representative images
are shown. Scale bar = 50 µm; (K–M) CD31+ cells (red color) were surrounded with GFAP+ astrocytes
(green color). Blue color indicates DAPI-positive nuclei. Scale bar = 20 µm. Values represent
mean + SEM.
2.3. The Synergistic Effects of SCs and an EE pregulate ngioge ic actors
T identify the growth factors associated with MSC graftin and EE-induced astrocyte ctivation,
the protein levels of mouse specific 10 candidate factors were measured in bas l ganglia tissue s mples
using an array-based multiplex ELISA assay. Among tested the factors, FGF-2, vascular cell adhesion
protein-1 (VCAM-1) a d matrix metalloprotein se-2 (MMP-2) were significantly increased in the
MSC-EE group compared with the PBS-CON groups at two w eks post-treatment (Figure 4A–C;
p < 0.01 and p < 0.05). However, the following factors were not synergistically elevated in mice treated
with the MSC-EE combi ation compared wit mice in the other gr ups: e id rmal growth factor
(EGF), granulocyte colony-stimulating factor (GCSF), hepatocyte growth factor (HGF), insulin-like
growth factor-1 (IGF-1), leptin, stromal cell-d rived factor-1 (SDF-1), and VEGF. These results sugg st
that angiogenic factors such as FGF-2, VCAM-1, and MMP-2 se retion were enhanced through an
EE after MSC transplantation, and that this role may involve angiogenesis nd activated astrocytes.
To identify the r wth factors derived from which origin, mouse or human cells, we assessed these
factors using a h man-specific array-based multiplex ELISA assay. As a result, 10 andidate factors
were not synergistically elevated. Furthermore, the levels of gro th fact rs derived from mouse c lls
were expressed markedly higher than those from human-derived MSCs (Figure 4A–J). This r sult
suggested that these factors were derived from mouse cells not human origin.
2.4. Astrocytes Co-Cultured with MSCs Secrete Angiogenic Factors
To confirm the effects of grafted MSCs on endogenous astroglial reaction in vivo, the angiogenic
factors released by astrocytes co-cultured with MSCs were analyzed using Western blotting. The levels
of ANGPT-1 (4.43 ± 0.15, p < 0.01) and ANGPT-2 (2.31 ± 0.25, p < 0.001) were significantly
increased in astrocytes co-cultured with MSCs compared with astrocytes cultured alone (3.78 ± 0.12
and 1.48 ± 0.12, respectively) and MSCs (1.00 ± 0.12 and 1.00 ± 0.02, respectively) (Figure 5A–C).
This result suggests that astrocytes would be stimulated by grafted MSCs and it released angiogenic
factors including ANGPT-1 and ANGPT-2. We have quantified the levels of GFAP in activated
astrocytes by MSCs, cultured astrocyte or MSCs alone to confirm stimulation by MSCs using Western
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blotting. As a result, the astrocytes co-cultured with MSCs and astrocytes cultured alone increased the
expression of GFAP (5.70 ± 0.20 and 5.02 ± 0.33, respectively, p < 0.001) compared to MSCs cultured
alone (1.00 ± 0.08, respectively).
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Figure 4. The angiogenic factors increased in the striatum of MSC-EE mice. (A–J) Two weeks after
MSC transplantation and exposure to EE, the striatum were lysed and the levels of angiogenic proteins
including FGF-2, VCAM-1, MMP-2, HGF, GCSF, EGF, IGF-1, SCF-1a, and Leptin were determined
by a mouse-specific ELISA array; (A–C) The levels of FGF-2, VCAM-1 and MM -2 were significantly
higher in the right neostriatum of MSC-EE mice than it was in the PBS-CON tissues two weeks after
treatment (* p < 0.05 and ** p < 0.01, n = 5, 4, 4, and 4 for PBS-CON, PBS-EE, MSC-CON, and MSC-EE,
respectively). In a human-specific ELISA array, most of proteins were not detected. Values represent
mean + SEM.
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Figure 5. Stimulated astrocytes by MSCs released angiogenic factors: (A) representative images of
Western blot analysis; (B,C) when astrocytes co-cultured with MSCs were cultured, angiogenic factors,
such as ANGPT1 and ANGPT2, were significantly increased compared to cultured astrocytes alone
and cultured MSCs alone (** p < 0.01 and *** p < 0.001, respectively, n = 3 each); and (D) the astrocytes
co-cultured with MSCs and astrocytes cultured alone increased the expression of GFAP compared with
MSCs groups (*** p < 0.001, n = 3 each). Values represent mean + SEM.
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2.5. Rotarod Performance and Grip Strength Results Indicate that an EE Synergistically Improves
Neurobehavioral Function after MSC Transplantation
To determine whether MSCs and an EE can restore neurobehavioral function, we performed
rotarod tests both at constant (48 and 64 rpm) and accelerating (4 to 80 rpm) speeds at two and eight
weeks post-treatment. The MSC-EE mice exhibited a tendency of improvement in rotarod performance
at two weeks post-treatment when the test was performed at a constant speed of 48 or 64 rpm
and also at an accelerating speed; but no significant differences were observed among the groups
(Figure 6A–C). Importantly, at eight weeks post-treatment, the MSC-EE mice (101.5 ± 19.8 s) exhibited
a significantly longer latency period than the mice in the other groups: MSC-CON (21.9 ± 3.0 s),
PBS-EE (68.5 ± 16.2 s) and PBS-CON (21.0 ± 3.5 s) at 48 rpm (Figure 6D; p < 0.001 compared with
MSC-CON and PBS-CON groups). At 64 rpm speed at eight weeks post-treatment, the MSC-EE
mice (57.4 ± 18.4 s) exhibited a significantly longer latency period than the mice in the other groups:
MSC-CON (8.0± 2.6 s), PBS-EE (40.5± 14.9 s) and PBS-CON (5.4± 1.6 s) (Figure 6E; p < 0.05 compared
with MSC-CON and PBS-CON groups). Similarly, the MSC-EE mice had the best rotarod test results
(166.7 ± 14.2 s) among the groups at eight weeks post-treatment when the test was performed at
an accelerating speed, compare to MSC-CON (109.6 ± 11.3 s) and PBS-CON mice (78.6 ± 6.4 s)
(Figure 6F; p < 0.01 and p < 0.001 compared with MSC-CON and PBS-CON groups, respectively).
PBS-EE (134.6 ± 12.2 s) group also significantly increased latency time compared with PBS-CON
(Figure 6F; p < 0.01 compared with PBS-CON group). These results suggest that MSC transplantation
alone is not sufficient for functional recovery, and that the combination of an EE and MSCs could
enhance sustained neurobehavioral improvement.
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with the PBS-CON controls (12.0 ± 7.7) (Figure 7B; p < 0.05 by one-way ANOVA). Interestingly, the
grip power of the ipsilateral control limb was enhanced only in the MSC-EE mice (32.5 ± 8.2), not
in the MSC-CON (4.8 ± 5.2), PBS-EE (18.2 ± 5.5), or PBS-CON mice (2.8 ± 7.0) (Figure 7B; p < 0.05
compared with MSC-CON and PBS-EE groups). This result suggests that the combination of EE and
MSC transplantation was effective in improving muscle power after unilateral ischemic brain damage.
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3. Discussion
The present study demonstrated that an EE exerts synergistic effects on hypoxic-ischemic brain
injury after MSC transplantation. Activated astrocytes released angiogenic factors including FGF-2,
VCAM-1, and MMP-2 without forming glial scars. Furthermore, we found that astrocytes exhibited
enhanced angiogenesis to induce functional recovery. Since our data indicate that an EE enhances
angioge esis and astrocyte-mediated secretion of angiogenic factors in the presence of MSC stimulation,
we propose that an EE and MSC tra spla tation are effective treatmen s for cerebral palsy (CP).
Hypoxic-ischemic brain injury is a major cause of dama in the fetal and neonatal p riods and
occurs in 2~3 of every 1000 full term infants [27,28]. This type of brain injury can result in permanent
disabilities such as CP, mental retardation, learning disabilities, and epilepsy [28,29]. Moreover, the
treatments for the chronic stages of these diseases are extremely limited, because of the difficulty in
inducing regeneration.
Stem cell therapy (e.g., neural stem/precursor cells and MSCs) is another potential treatment that
has been used to promote regeneration in brain damage. Of all stem cell types, MSCs are abundantly
harvested from bone marrow, umbilical cord blood, or adipose tissue and can be used in tissue
engineering [6]. Recent evidence suggests that MSCs can produce several beneficial growth factors
(e.g., HGF, IGF-1, VEGFA, BDNF, and NGF) [30–32], thereby affecting par crine mechanisms rather
t n cell replacement and dir ct tissu egeneration. Systemic injection of MSCs has been shown to
promote functional recovery in spinal cord injury [33]; however, di ect injection of these cells did
not significantly enhance behavioral functions [3]. Since grafted cells are often limited to homing by
the immune system, cell therapy alone may not be sufficient for functional restoration. Thus, cell
transplantation alone may be not sufficient to achieve stable beneficial effects for neurorestoration
because of engraftment limitations [34].
The beneficial effects of physical training as rehabilitation, such as an EE, have been reported
in animal studies. An EE is known to induce the release of neurotrophic factors (e.g., BDNF,
NGF, GDNF, and FGF-2) that have important roles in restoration [4,35–37], increasing neuronal
plasticity [5,38] and reducing lesion size [39]. Several studies have revealed that an EE can induce
Int. J. Mol. Sci. 2016, 17, 1550 9 of 15
angiogenesis via angiogenic factors and can also stimulate astrocyte activation, which supports
angiogenesis [4,40]. Similarly, we have demonstrated the beneficial effects of an EE with respect
to neurogenesis, angiogenesis, synaptogenesis, and functional improvement in normal and injured
mice [3–5].
One previous study reported that an EE enhances the integration and neurogenic fate of
transplanted cells [3]. Therefore, the EE has been expected to become part of therapies that can
overcome the limitations of cell transplantation. In addition with neurogenesis, recent studies have
shown that astrocytes, which are the most abundant cells in the brain, play important roles in the
transport of glutamate, maintenance of homeostasis and the BBB, modulation of inflammation, and
secretion of neurotrophic factors [7,41,42]. When the brain is damaged, astrocytes are transformed
to their reactive state. If this state persists, glial scars are formed, followed by astrocyte retraction of
their endfeet connections to blood vessels. However, since angiogenesis is an essential part of brain
injury [4], astrocytes are believed to be important for recovery. Recent studies have suggested that
MSC transplantation can stimulate astrocytes, which release beneficial factors such as GDNF, VEGF,
FGF-2, and BDNF [21–26]. Moreover, MSCs have been shown to inhibit the formation of glial scars in
a rat model of stroke [22,32,43].
In the present study, among the protein levels of ten candidate factors associated angiogenesis,
FGF-2, VCAM-1, and MMP-2 were significantly increased in the basal ganglia of MSC-EE mice.
However, most of proteins were not detected in human Quantibody® array. This result suggested that
these factors were derived from mouse cells not human origin.
In our mouse model of hypoxic-ischemic brain injury, we found that activated astrocytes after
MSC treatment were associated with angiogenesis and functional recovery. In addition, astrocytes
cultured in vitro with MSCs released more angiogenic factors, including ANGPT1 and ANGPT2, than
astrocytes cultured alone. Furthermore, Gao et al. suggested that MSCs can increase astrocyte survival
via the phosphoinositide 3-kinase/threonine protein kinase pathway and enhance the expression of
a gap junction protein, connexin 43, which is derived from astrocytes in vitro [22,44,45]. Therefore,
astrocyte-mediated growth factors stimulated by MSCs might help restore BBB integrity.
Interestingly, astrocyte activation and secretion of angiogenic factors were robustly increased at
earlier stage (two weeks after treatment) and angiogenesis was exhibited at later stage (eight weeks
after treatment). This result suggests that beneficial environment with upregulation of angiogenic
factors has driven to be restored by an EE and MSC transplantation, and thereafter angiogenesis
was significantly increased, consequently resulting in functional recovery in the neurobehavioral
outcomes. Our results show that motor function and forelimb muscle power were enhanced by an
EE after MSC treatment, suggesting that neurological behavior was synergistically improved with
the combination treatment of cell therapy and an EE. We also found that endogenous angiogenesis
in parallel with upregulation of angiogenic factors including FGF-2, VCAM-1, MMP-2, ANGPT-1
and ANGPT-2 released from activated astrocytes in vivo and in vitro, enhances functional recovery
through synergistic effects of the EE and MSC combination in mice with hypoxic-ischemic brain injury.
4. Materials and Methods
4.1. Animals
Mice were housed under climate-controlled conditions with a 12-h light/dark cycle and were
provided standard food and water ad libitum. Mice of both sexes were used. All procedures were
reviewed and approved by the Animal Care and Use Committee of Yonsei University College of
Medicine (identification code: 2013-0209) on 11 July 2013.
4.2. Neonatal Hypoxic-Ischemic Brain Injury
Permanent ischemic brain damage was induced in 7-day-old CD-1® (ICR) mice by unilateral
right carotid artery ligation. Hypoxic brain injury (8% O2 for 90 min) was induced as previously
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described [3]. Body temperature was maintained at 37 ◦C within the hypoxic chamber. One week
after HI brain injury, a scalp incision was made to identify the brain lesion in the posterolateral
area of the right hemisphere. The presence and extent of brain injury in all subjects were assessed
through the semi-transparent skull. Animals with severe brain lesions covering more than 50% of the
unilateral hemisphere were excluded to eliminate potential sampling error due to volumetric changes
in the neostriata.
4.3. Cell Transplantation
At Postnatal Week 6 (P42), mice were anesthetized with ketamine (100 mg/kg) and xylazine
(10 mg/kg) by intraperitoneal (i.p.) injection. Mice were randomly assigned to one of two groups for
treatment with either MSCs or PBS. The mice received an intrastriatal injection of MSCs (1 × 105 cells,
2 µL volume, 0.01 µL/s infusion rate) or PBS using stereotaxic coordinates (AP +0.5 mm from bregma;
ML −1.5 mm from bregma; DV −3.5 mm from the dura). Body temperatures were maintained at 37 ◦C
in a heating chamber during the recovery period.
4.4. Grouping and Experimental Housing
A total of 116 mice were recruited in this study. After stereotaxic surgery, 56 mice were randomly
assigned in four groups for 2 weeks cohort: PBS-CON (n = 13), PBS-EE (n = 13), MSC-CON (n = 15),
and MSC-EE (n = 15). For 8 weeks cohort, 60 mice were randomly assigned in four groups: PBS-CON
(n = 15), PBS-EE (n = 15), MSC-CON (n = 15), and MSC-EE (n = 15). Whereas the SC controls were
housed for the same duration in a standard cage (27 × 22.5 × 14 cm3) without social interaction
(3–4 mice/cage), the EE mice were housed in a spacious cage (86 × 76 × 31 cm3) containing novel
objects such as tunnels, shelters, toys, and running wheels for voluntary exercise. In addition, the EE
mice were allowed social interaction (12–15 mice/cage) for up to 2 months (Figure 1D). All animals
were housed in a facility accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) and were given food and water ad libitum with alternate 12-h light/dark
cycles, according to animal protection regulations. The experimental procedure was approved by
the relevant institutional review board (IRB). A schematic timeline of the experiment from birth to
14 weeks of age is provided in Figure 1A.
4.5. Behavioral Assessment
ROTAROD PERFORMANCE: A rotarod test was used to assess motor coordination and balance.
All animals received a preoperative performance evaluation at 5–6 weeks of age. The rotarod tests
were then performed at 2-week intervals until 8 weeks post-transplantation using constant speed
(48 and 64 rpm) and accelerating speed (4–80 rpm) paradigms. The latency time of each mouse to fall
from the rod was measured twice during each test; individual tests were terminated at a maximum
latency time of 300 s [3].
GRIP STRENGTH TEST: A grip strength test was performed using the SDI Grip Strength
System (San Diego Instruments Inc., San Diego, CA, USA), which includes a push-pull strain gauge.
A triangular piece of metal wire 2 mm in diameter was used as the grip bar. Each animal was held
near the base of its tail and was moved in close proximity to the bar until the animal could grip the bar
with its forepaws. Peak force was automatically registered in gram-force by the apparatus. The mean
peak force of three trials was used for analysis [3].
4.6. Cell Culture: Co-Culture System
Mouse astrocytes (Astrocyte Type 1 clone, ATCC, CRL-2541) and MSCs were cultured in
Dulbecco’s modified Eagle’s medium-H (DMEM-high glucose; No. 30-2002, American Type Culture
Collection (ATCC), Manassas, VA, USA) and DMEM-L (DMEM-low glucose; No. 11885-084, Gibco,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 1% antibiotics (P/S). MSCs
(1 × 105 cells) were cultured on the upper side of a Falcon 0.4 µm cell-culture insert (No. 353090, BD
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Bioscience, San Jose, CA, USA) in 2 mL medium, with 5 × 105 astrocytes cultured on the opposite
side of the insert plate in 3 mL medium, in a total of 5 mL medium (n = 3/group). As negative
controls, MSCs and astrocytes were cultured alone. After the cells had adhered to the insert well, they
were washed with Hank’s Balanced Salt Solution (HBSS, Gibco) four times, and then the media were
replaced with serum-free media that can culture astrocytes. After 48 h, protein was extracted from the
cells for Western blot analysis.
4.7. Immunohistochemistry
Immunohistochemistry was performed as previously described [46]. Briefly, animals were
euthanized and perfused with 4% paraformaldehyde (PFA). The harvested brain tissue samples
were cryosectioned with a slice thickness (16-µm), and immunohistochemistry staining was performed
on four sections over a range of 128 µm. Sections were stained with primary antibodies against GFAP
(1:400, Abcam, Cambridge, UK), CS-56 (1:200, Abcam), a-SMA (1:200, Abcam), and CD31 (1:200, BD
Bioscience, San Jose, CA, USA). For visualization, the following secondary antibodies were used: Alexa
Fluor® 594 goat anti-rat (1:400, Invitrogen, Carlsbad, CA, USA), Alexa Fluor® 594 goat anti-rabbit
(1:400, Invitrogen), and Alexa Fluor® 488 goat anti-mouse (1:400, Invitrogen). Tissue samples were
mounted on glass slides with fluorescent mounting medium containing 4’,6-diamidino-2-phenylindole
(DAPI; Vectorshield, Vector, Burlingame, CA, USA). The stained sections were then analyzed using
a confocal microscope (LSM700, Zeiss, Gottingen, Germany) and the MetaMorph Imaging System
(Molecular Device, Sunnyvale, CA, USA). Blood vessel density was evaluated using a fluorescence
microscope (BS51, Olympus, Tokyo, Japan) and the MetaMorph Imaging System. Images of glial
scarring were captured using a fluorescence microscope (Axio Imager M2, Zeiss); scarring density was
evaluated using ZEN Imaging Software (Blue edition, Zeiss).
4.8. Assessment of Growth Factors in the Striatum
To identify growth factors that are regulated by MSC transplantation and/or an EE, neostriata
were separated from the surrounding brain tissue and lysed in 200 µL of cold RIPA buffer (50 mM
Tris-HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% sodium
deoxycholate) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Tissue
lysates were then centrifuged at 13,000× g for 15 min at 4 ◦C. The supernatants were harvested, and
the protein concentrations were determined using a protein assay kit (Bio-Rad, Hercules, CA, USA).
An array-based multiplex ELISA assay (Mouse Quantibody® array, RayBiotech, Norcross, GA, USA)
was used to determine which of the following 10 mouse cytokines or growth factors were detectable in
the neostriata: FGF-2, EGF, GCSF, HGF, IGF-1, LEP, MMP-2, SDF-1a, VCAM-1, and VEGF. Expression
of angiogenic factors was detected using an array scanner (Gene PIX™ 4000B, Axon instruments,
Sunnyvale, CA, USA).
4.9. Western Blotting
Harvested cells were lysed in 50 µL cold lysis buffer (50 mM Tris-HCl, pH 7.5, 1% Triton X-100,
150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate) with a protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO, USA). Lysates were then centrifuged at 13,000× g for 15 min
at 4 ◦C. The supernatants were harvested, and the protein concentrations were determined using a
protein assay kit (Bio-Rad Laboratories). Proteins (20 µg) were solubilized in sample buffer (60 mM
Tris-HCl, pH 6.8, 14.4 mM β-mercaptoethanol, 25% glycerol, 2% SDS, and 0.1% bromophenol blue),
denatured for 10 min at 90 ◦C, and subjected to electrophoresis on a 10% SDS polyacrylamide gel.
The resolved proteins were then transferred onto a 0.2 mm InvitrolonTM polyvinylidene difluoride
(PVDF; Invitrogen) membrane using an XCell IITM Blot Module (Invitrogen). The membranes
were blocked for one hour in TBST (Tris-buffered saline (10 mM Tris-HCl, pH 7.5, 150 mM NaCl)
containing 0.05% Tween 20) supplemented with 5% nonfat dry milk (Bio-Rad Laboratories) at room
temperature and washed three times with TBST. After blocking, the membranes were incubated
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at 4 ◦C overnight in TBST supplemented with 5% nonfat dry milk and the appropriate primary
antibodies. Membranes were incubated with antibodies against ANGPT1 (1:500, Abcam), ANGPT2
(1:500, Abcam), GFAP (1:500, Abcam), and Actin (1:1000, Santa Cruz Biotechnology Inc., Dallas,
TX, USA). The blots were then washed three times with TBST and incubated for one hour with
horseradish peroxidase-conjugated secondary antibodies (1:3000, Santa Cruz Biotechnology) at room
temperature. After washing three times with TBST, immunoreactive bands were visualized with an
enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Little Chalfont, UK).
4.10. Statistical Analysis
All data are expressed as mean± SEM. Differences between groups were analyzed using one-way
analysis of variance (ANOVA) followed by a post-hoc Bonferroni comparison. All analyses were
performed using SPSS software (IBM Corporation, Armonk, NY, USA; version 20.0). A p value < 0.05
was considered statistically significant.
5. Conclusions
Our findings demonstrate that MSC transplantation and an EE synergistically promoted
neurological function by enhancing endogenous angiogenesis and astrocyte activation and
upregulating angiogenic factors including FGF-2, VCAM-1, and MMP-2. Similarly, we found that
MSC-activated astrocytes secreted angiogenic factors in vitro. Therefore, our results indicate that a
rehabilitative strategy combined with a cell-based therapy may be an effective combination for treating
angiogenesis in CP. Moreover, an EE could be a useful strategy for enhancing other desirable effects
from cell therapy in additional neurological diseases.
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